Research Overview
At the forefront of cancer research, the Molecular Oncology Laboratory, under the leadership of Dr. Valsamo Anagnostou, is actively engaged in groundbreaking investigations. Our focus spans the entire spectrum of tumor and immune evolution, utilizing advanced analytical techniques to probe the molecular intricacies that determine therapeutic outcomes.
In the realm of integrative genomic exploration, we delve into the genetic factors influencing responses to immunotherapy. Through sophisticated multi-omic analyses, we decode gene expression patterns underlying immunotherapeutic responses and resistance, providing insights into the molecular signatures of treatment efficacy. Additionally, our laboratory is at the forefront of liquid biopsy innovation. We develop assays that capture dynamic changes in response to immunotherapy, offering a more accurate prediction of the emergence of resistance.
Research Projects
Our overarching objective is to study the temporal and spatial dynamics of the metastatic and immune cascade under the selective pressure of immunotherapy. By gaining a deeper understanding of these processes, we aim to pave the way for “next-generation” immuno-oncology clinical trials.
Ultimately, our efforts strive to redefine how oncologists select patients for immunotherapies, ushering in a new era of precision oncology. The Molecular Oncology Laboratory is committed to driving transformative changes in cancer care through rigorous scientific research and innovative clinical applications.
Clinical Translation
Beyond basic research, the Molecular Oncology Laboratory actively translates findings into clinical applications. Dr. Anagnostou’s work forms the basis for a clinical trial in collaboration with the Canadian Cancer Trials Group focusing on ctDNA response adaptive immuno-chemotherapy in NSCLC. In this paradigm-shifting approach, therapeutic decisions are guided by molecular responses derived from liquid biopsies, challenging the conventional reliance on imaging.
